Navigation Links
XBiotech to Present at UBS Global Healthcare Conference
Date:5/1/2013

AUSTIN, Texas, May 1, 2013 /PRNewswire/ -- XBiotech announced today that John Simard , Chairman, President & Chief Executive Officer, will present at the UBS Global Healthcare Conference in New York, NY on Monday, May 20th at 1:30pm ET.  The conference will take place at the Sheraton New York Hotel May 20-22, 2013.

John Simard remarked "XBiotech is delighted to be invited by UBS to present at this prestigious venue. UBS is one of the greatest financial institutions in the world and we are indeed honored to be asked to share our story at their conference."

About True Human™ Antibodies
True Human antibodies represent the next generation of therapeutic antibodies. True Human antibodies are "invisible" to the body's immune system and thus have the potential for better safety, efficacy and patient tolerability compared to earlier generation antibody therapeutics.

About XBiotech
XBiotech is pioneering breakthrough therapies that improve the safety and efficacy of antibody therapeutics. The Company's lead product candidate inhibits chronic sterile inflammation by targeting IL-1a, a master regulator of inflammation. The clinical development program addresses tremendous unmet medical need in multiple disease indications including, acne, psoriasis, cachexia, cancer, type 2 diabetes and cardiovascular disease. XBiotech is also revolutionizing scalable, flexible manufacturing systems for the production of biological therapies.  Using minimal infrastructure and disposable bioreactor technology – to dramatically reduce capital requirements, operating complexity, and lead times - the Company has established a compelling commercialization path for its True Human antibody platform.  XBiotech is building on a foundation of groundbreaking therapies, innovation and a commitment to unmet medical needs worldwide. For more information on how XBiotech is advancing human monoclonal antibody therapy please visit www.xbiotech.com.

Contact: 
Investors: 
Erika Geimonen, Ph.D.
XBiotech
info@xbiotech.com
512.386.2906                                                        


'/>"/>
SOURCE XBiotech
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
2. XBiotech Reports Positive Phase II Interim Analysis Results From Type 2 Diabetes Study
3. Leonhardt Ventures to Present Technology Showcase @ Heart Rhythm 2013
4. Vatsala Naageshwaran of Absorption Systems to Present at Disso 2013 International Conference in Mumbai, India on May 3rd
5. Organogenesis to Present Large Retrospective Comparative Effectiveness Analysis and Health Economic Data in Chronic Wound Healing at The Symposium on Advanced Wound Care and Wound Healing Society Meeting
6. Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting
7. Epilepsy Foundation To Present Epilepsy Therapy Project Lifetime Accelerator Award To Henrik Klitgaard, Ph.D., Recognizing Contributions To New Therapies
8. Neuralstem ALS Trial Data Presented At The American Association Of Neurological Surgeons Annual Meeting
9. Anterios, Inc. CEO And Founder, Jon Edelson, To Present At Needham & Companys 12th Annual Healthcare Conference
10. Rush University Medical Center Presents Positive MuGard Clinical Data at the Oncology Nursing Society 38th Annual Congress
11. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2017)... Ind. , June 13, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that the U.S. Food and Drug ... dated June 3, 2015 relating to its Zhejiang, ... "The successful clearance of the ... manufacturing facility is a measure of the progress ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
(Date:6/9/2017)... 9, 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders ... design, manufacture, sale and distribution of the AeroForm® Tissue ... of its commercial roll-out in the United ... than one hundred (100) medical institutions and health systems, ... a needle-free alternative for women who choose reconstructive surgery ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Park Systems , a leader in Atomic ... SEMICONWest attendees and Park customers on July 11, 2017 from 12-2pm at the ... Chairman & CEO of Park Systems, and Prof. Krishna Saraswat , Rickey/Nielsen Professor ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, ... regions access to insurance assistance and financial planning services, is announcing the commencement ... families in the region facing financial crisis. , Matthew 25: Ministries (M25M) is ...
(Date:6/27/2017)... ... 2017 , ... Excel Medical, the leader in Next-Generation Medical ... Executive Vice President, Sales and Marketing. Finnegan is a widely known industry leader ... leadership. He has received industry recognition for innovations and new approaches to sales ...
(Date:6/27/2017)... , ... June 27, 2017 , ... Harbour , ... token assets on the Ethereum blockchain, has released their technical specifications . , ... there has been little systematic approach for determining which offerings will garner the greatest ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Association’s SUNucate efforts, Louisiana became the sixth state to pass legislation which ... Governor John Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, ...
Breaking Medicine News(10 mins):